SecBot SecBot
PRESS-RELEASE ·Filed Nov 2, 2026

QURE

uniQure Inc.
BULLISH
Impact 7/10
Horizonmonths Processed14d 16h ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The PDUFA date is May 1, 2027, with an AdCom likely in early 2027. The confirmatory trial screening start by end of 2026 is a near-term catalyst. Monitor AdCom outcome and any safety/efficacy signals from the ongoing Phase I/II data. The stock's 3.1% normal daily move suggests a binary event of this magnitude could drive a multi-standard-deviation move.

DirectionBullish
Confidencehigh
Horizonmonths

AMT-130

▲ Bullish Named in this press release
Impact
Phase
Phase 1/2 (pivotal for accelerated approval)
Time to market
BLA submission planned for Q3 2026; FDA accelerated approval decision likely 6-10 months after submission (potentially H1 2027)
Next catalyst
None dated

What to watchThe BLA submission in Q3 2026 is the key near-term catalyst. The FDA has already aligned on the submission package, but final acceptance and review timelines remain to be seen. Watch for the official BLA filing announcement, PDUFA date assignment, and any FDA Advisory Committee meeting. The $225M June 2026 offering funds commercialization readiness but added ~8% dilution. Analysts are bullish (16 buy vs 5 hold, mean PT ~$64.59, ~47% upside from ~$44).

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$22.97
T+0 close · Nov 2, 2026 · via day close
Latest settled
−0.78%
T+5 · $22.79 · next T+20 in 14d
Vs SPY
−0.86%
α at T+5
Latest observation
+0.82%
T+9 · FF3 residual α
  1. T+0 · Nov 2 $22.97entry
  2. T+1 · 14d ago +3.92%α +3.62% · $23.87
  3. T+5 · 8d ago −0.78%α −0.86% · $22.79
  4. T+10 · todayOpen
  5. T+20 · in 14d Pending
  6. T+60 · in 2mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

uniQure announced FDA acceptance and Priority Review of its BLA for ifezuntirgene inilparvovec (AMT-130), a gene therapy for Huntington's disease, with a PDUFA target action date of May 1, 2027. The FDA plans an Advisory Committee meeting and the confirmatory Phase III trial is expected to begin screening by end of 2026. If approved, this would be the first disease-modifying treatment for Huntington's disease, a large unmet need with ~75,000 patients in the US, EU, and UK.

Key Facts

  • FDA accepted BLA for ifezuntirgene inilparvovec (AMT-130) for Huntington's disease under Accelerated Approval pathway
  • Granted Priority Review with PDUFA target action date of May 1, 2027
  • FDA tentatively planning an Advisory Committee meeting
  • BLA supported by 36-month Phase I/II data vs. propensity score-matched external control from Enroll-HD database
  • Confirmatory trial design aligned with FDA: randomized 2:1 vs standard of care, ~200 patients, TFC primary endpoint at 36 months; screening to begin by end of 2026
  • First investigational therapy for Huntington's disease to receive Breakthrough Therapy and RMAT designations; also holds Fast Track designation
  • Approximately 75,000 people have Huntington's disease in the US, EU, and UK; no approved disease-modifying therapies exist
  • Market cap ~$1.8B; normal daily move 3.1%

Financial Impact

First disease-modifying treatment for a large unmet-need population of ~75,000 patients in developed markets; no approved competitors. Approval would transform uniQure's revenue profile from its current hemophilia B gene therapy base.

revenuemarket cap

Risk Factors

  • FDA may require additional data from the confirmatory trial before granting full approval; Accelerated Approval is not guaranteed
  • AdCom vote could be negative or split, creating uncertainty
  • Phase I/II data, while supportive, is from a small non-randomized study with an external control, FDA may view the evidence as insufficient for accelerated approval
  • Manufacturing or CMC issues could delay approval or result in a CRL
  • If approved, commercial adoption depends on pricing, reimbursement, and the logistical complexity of MRI-guided neurosurgical delivery

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3393020

Track record

38 reports on QURE

Performance horizon

5 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 7 of 10 went positive at some point.

Filters
  1. Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
  2. Nov 4, 202612d ago 8-K Bullish 7/10 No price data
  3. Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
  4. Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
  5. Nov 2, 202614d ago Press Release Bullish 7/10 Viewing Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
  6. Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
  7. Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
  8. Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
  9. Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
  10. Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (10h 11m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026